Biotechnological devices and products from are made to the ones who need them in certain businesses and firms. International biotech labs and subsidiaries with their subsequent product pipeline are integrated in order to deliver the needed demands in the market. Mentioning one of the key players in here is the BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical Inc. is a company that specialises in the biotech industry. Based in their corporate headquarters in San Rafael, California, it has several locations and offices worldwide. The company’s main business is in enzyme replacement therapies (ERTs). In addition, they were the first biotech company which provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). Also, they were the first proponents to provide therapeutics for phenylketonuria (PKU). The BioMarin pharmaceutical stock is available publicly as well and is open for internship.

BioMarin Pharmaceutical Inc. Headquarters Address

Traded as (BMRN Stock) NASDAQ: BMRN
Industry focused Biotechnology
Founded in 1997
Founder Jean-Jacques Bienaime, Henry J. Fuchs, Dan Spiegelman
Headquarters/Based in San Rafael, CA, USA
Products Biotechnological products

Contact

  • Address Location: 770 Lindaro Street, San Rafael, CA 94901, USA
  • Contact number: 415-506-6700
  • Website: http://www.bmrn.com

BioMarin Pharmaceutical Subsidiaries

  • Prosensa
  • BioMarin Europe Ltd.
  • BioMarin International Ltd.
  • Huxley Pharma.

BioMarin Pharmaceutical Inc. Profile/Overview

  • In 1997, BioMarin was founded by men named Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and successfully went public in 1999. Other proponents were MPM Bioventures, Grosvenor Fund and Florian Schönharting. In 2002, BioMarin made an acquisition to Glyko Biomedical.
  • In 2009, another acquisition was made to Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, marketing approval was granted to the company by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). BioMarin made a product launch of this under the name Firdapse.
  • In 2010, BioMarin made another acquisition to LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers.
  • In 2012, the company made acquisition to Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
    In November 2014, the company successfully acquired Prosensa for up to $840 million, the range of treatments for Duchenne Muscular Dystrophy however failed to attain FDA approval and in May 2016 development ceased.

BioMarin Pharmaceutical Inc. Products/Capabilities

  • BioMarin Pharmaceutical Inc. is dedicated in the successful development and commercialization of pharmaceuticals for serious diseases and medical conditions worldwide. Its commercial products include the following:
  1. Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease
  2. Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease
  3. Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI
  4. Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.
  • Clinical trial candidates of BioMarin include:
  1. Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease
  2. pegvaliase, an enzyme substitution therapy for the treatment of PKU
  3. vosoritide, a peptide therapeutic for the treatment of achondroplasia
  4. BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A
  5. BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.